Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v2.4.0.6
Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2011
Dec. 31, 2010
ASSETS    
Cash and cash equivalents $ 5,882 $ 8,691
Marketable securities 14,408 6,008
Prepaid expenses and other current assets 254 473
Restricted cash   471
Total current assets 20,544 15,643
Property and equipment, net 543 271
Other assets 1,349 290
Total assets 22,436 16,204
LIABILITIES AND STOCKHOLDERS' EQUITY    
Accounts payable 2,389 252
Accrued clinical and development expenses 4,465 2,439
Accrued liabilities 1,737 823
Total current liabilities 8,591 3,514
Warrant liability 9,209 7,499
Deferred rent 153 248
Total liabilities 17,953 11,261
Commitments and contingencies (Note 7)      
Stockholders' equity:    
Preferred stock, $0.001 par value: Authorized: 2,000,000 shares authorized; no shares issued and outstanding.      
Common stock, $0.001 par value: Authorized: 150,000,000 shares at December 31, 2011 and 2010; Issued and outstanding: 49,128,475 and 33,702,242 shares at December 31, 2011 and 2010, respectively 49 34
Additional paid-in capital 256,563 231,383
Accumulated other comprehensive (loss) income (1) 1
Deficit accumulated during the development stage (252,128) (226,475)
Total stockholders' equity 4,483 4,943
Total liabilities and stockholders' equity $ 22,436 $ 16,204